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Abstract
Triclosan is an antimicrobial chemical incorporated into many personal, medical and household 
products. Approximately, 75% of the U.S. population has detectable levels of triclosan in their 
urine, and although it is not typically considered a contact sensitizer, recent studies have begun to 
link triclosan exposure with augmented allergic disease. We examined the effects of dermal 
triclosan exposure on the skin and lymph nodes of mice and in a human skin model to identify 
mechanisms for augmenting allergic responses. Triclosan (0%–3%) was applied topically at 24-h 
intervals to the ear pinnae of OVA-sensitized BALB/c mice. Skin and draining lymph nodes were 
evaluated for cellular responses and cytokine expression over time. The effects of triclosan (0%–
0.75%) on cytokine expression in a human skin tissue model were also examined. Exposure to 
triclosan increased the expression of TSLP, IL-1β, and TNF-α in the skin with concomitant 
decreases in IL-25, IL-33, and IL-1α. Similar changes in TSLP, IL1B, and IL33 expression 
occurred in human skin. Topical application of triclosan also increased draining lymph node 
cellularity consisting of activated CD86+GL-7+ B cells, CD80+CD86+ dendritic cells, 
GATA-3+OX-40+IL-4+IL-13+ Th2 cells and IL-17 A+ CD4 T cells. In vivo antibody blockade of 
TSLP reduced skin irritation, IL-1β expression, lymph node cellularity, and Th2 responses 
augmented by triclosan. Repeated dermal exposure to triclosan induces TSLP expression in skin 
tissue as a potential mechanism for augmenting allergic responses.
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consumer goods. Although triclosan has been in use in the United States since the 1960s, the 
FDA is re-evaluating its safety and efficacy. The CDC reports that triclosan is detected in 
the urine of 75% of the U.S. population (Calafat et al., 2008), a reflection of its ubiquitous 
use today. Triclosan is a small lipophilic compound that is readily absorbed through the 
skin. Many healthcare settings use triclosan-containing hand soaps and sanitizers to prevent 
nosocomial infections, and it was recently found that staff at hospitals that used triclosan-
containing hand soaps had increased concentrations of triclosan in their urine (MacIsaac et 
al., 2014). Although triclosan itself has low allergenic and irritation potential (Lachapelle et 
al., 1979) with few cases of contact dermatitis reported, analyses of data collected from the 
National Health and Nutrition Examination Surveys (NHANES) and others have revealed a 
positive association between urinary triclosan levels and diagnoses of allergy and hay fever 
(Clayton et al., 2011), allergic sensitization to air and food allergens (Bertelsen et al., 2013; 
Savage et al., 2012; Spanier et al., 2014), and increased asthma exacerbations (Savage et al., 
2014). Triclosan is incorporated into products at concentrations between 0.1% and 1%, and 
was found by our laboratory to augment allergic responses in a mouse ovalbumin (OVA) 
asthma model after 28 days of repeated dermal exposures to 0.75%–3% triclosan (Anderson 
et al., 2012). The mechanisms that promote these adjuvant effects are not yet known. 
Further investigations into the immunological mechanisms that augment allergic responses 
with repeated dermal triclosan exposure are needed.
We hypothesized that repeated dermal exposure to triclosan induces early changes in 
cytokine expression in the skin tissue and local draining lymph nodes that help promote 
allergic immune responses. Analyses of the early molecular and cellular changes in the skin 
tissue and skin draining lymph nodes (LN) after repeated dermal exposure to triclosan 
induce a unique cytokine expression signature in the skin that includes increased thymic 
stromal lymphopoietin (TSLP) expression in both mouse and human skin. In the lymph node 
(LN) we identified increases in antigen presenting cells (APCs), Th2 cells and IL-17+ CD4 
T cells. In vivo antibody blockade of TSLP significantly reduced the augmented allergic 
responses in the skin and LN. Dermal exposure to triclosan induces expression of TSLP in 
mouse and human skin tissue as a potential mechanism for augmenting allergic disease.
MATERIALS AND METHODS
Animals
Female BALB/cAnNTac (BALB/c) mice were purchased from Taconic and BALB/c-Tg 
DO11.10 (DO11.10) mice (6–8 weeks of age) from The Jackson Laboratory. Mice were 
housed 3–5 per cage in sanitized HEPA-filtered ventilated cages with sterilized hardwood 
chip bedding and nesting enrichment materials in the AAALAC-accredited NIOSH animal 
facility in Morgantown, WV. Mice were provided with NIH-31 modified irradiated rodent 
diet (Harlan) and autoclaved tap water ad libitum. Euthanization was performed by CO2 
asphyxiation. Animal procedures were performed according to the Guide for the Care and 
Use of Laboratory Animals and reviewed and approved by the NIOSH Animal Care and Use 
Committee.
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Chemical exposures—Triclosan (Calbiochem; CAS number 3380-34-5) was dissolved 
in acetone (Sigma) as a percent solution (weight/volume) at concentrations based on 
previous studies (Anderson, et al., 2012). For epicutanous exposures which we refer to here 
as dermal exposures, 25 μl of solution was pipetted onto the dorsal surface of both ears at 
24-h intervals for the durations indicated. Studies included 3–6 mice/exposure group 
depending upon the biological endpoint being evaluated.
Injections—For OVA sensitization, mice received 10μg of ovalbumin (OVA; Sigma) 
dissolved in USP grade PBS (Amresco) by intraperitoneal injection. Functional grade anti-
mouse TSLP (clone 28F12, eBioscience) or Rat IgG2a isotype control (eBR2a) antibodies 
were also prepared in PBS and injected intraperitoneally (200–400 μg). A timeline of the 
treatments is depicted in Figure 7A. For adoptive cell transfers, CD4 T cells were negatively 
selected using magnetic cell isolation (Stemcell) from pooled spleens and peripheral lymph 
nodes collected from DO11.10 mice. DO11.10 CD4 T cells (3 × 106) were adoptively 
transferred intravenously into BALB/c hosts just prior to OVA injections.
Ex Vivo Lymph Node Cell Stimulations
Superficial cervical lymph nodes draining the ears (LN) were collected, homogenized 
between frosted microscope slides and counted on a Cellometer (Nexcelom). Lymph node 
cells (5 × 105) were seeded into 96-well u-bottom plates with soluble anti-CD3 (5 μg/ml) 
and anti-CD28 (2 μg/ml) in RPMI media containing L-glutamine and HEPES (Cellgro) with 
7.5% fetal bovine serum (Hyclone), 50 μM 1-Mercaptoethanol and penicillin-streptomycin 
(Sigma-Aldrich) (cRPMI). Cells were incubated for 24 h in a humidified incubator 
(37°C/5% CO2). Cytokines in the supernatants were measured using Flowcytomix bead 
assay kits (eBioscience). For intracellular cytokine analyses, LN cells (1 × 106) were 
incubated in loosely capped 12 × 75 mm tubes in 500 μl cRPMI with leukocyte activation 
cocktail with Golgi Plug (BD) for 4 h.
Ear Histology and Protein Lysates
Ears were fixed in 10% neutral buffered formalin and embedded in paraffin. Tissues were 
sectioned at 5 μM and stained with Hematoxylin-Eosin (H&E) and evaluated using 
microscopy. Alternatively, ears (1 per mouse) were mechanically disrupted on a TissueLyser 
II (Qiagen) in T-PER protein extraction reagent (Pierce) and soluble proteins quantified by 
BCA protein assay (Pierce). Cytokines were measured in 25 μg of protein lysate using 
Flowcytomix bead assay kits (eBioscience) or measured in 100 μg of protein lysate by 
ELISA including TSLP (BioLegend), IL-25, and IL-33 (eBioscience).
Flow Cytometry
Cells were resuspended in staining buffer (PBS +1% bovine serum albumin+ 0.1% sodium 
azide) containing anti-mouse CD16/32 (clone 2.4G2) to block Fc receptors. PMA-stimulated 
cells were then additionally labeled with Live/Dead Aqua fixable solution (Life 
Technologies) for exclusion of dead cells. Cells were incubated with fluorochrome-
conjugated antibodies recognizing extracellular proteins: CD11b-PerCPCy5.5 (clone 
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M1/70), MHC class II-Alexa Fluor 700 (M5/114.15.2), DO11.10-TCR-FITC (KJ1-26), 
B220-Alexa Fluor 488 (RA3-0452), CD4-APC-eFluor 780 (GK1.5), CD44-Alexa Fluor 700 
(IM7), OX40-PE (OX-86), CD80-PE (16-10A1), and CD86-APC (GL1) from eBioscience 
and CD4-V500 (RM4-5), CD8-V500 (53-6.7), CD69-PE-CF594 (H1.2F3), and GL-7-Alexa 
Fluor 647 (GL7) from BD Biosciences. Cells were fixed in Cytofix buffer (BD Biosciences), 
and for intracellular cytokine staining, cells were also permeabilized with Perm Wash (BD 
Biosciences) containing 10% rat serum (Stemcell) and anti-mouse CD16/32. Cells were then 
incubated with fluorochrome-conjugated cytokine antibodies in perm wash: IL-4-Alexa 
Fluor 488 (11B11), IL-13-PE (13A) and TNF-α-PE-Cyanine7 (MP6-XT22) from 
eBioscience, IL-17-PE-CF594 (TC11-18H10), and IFN-γ-PE-CF594 (XMG1.2) from BD 
Biosciences and IL-2-BV42 (JES6-5H4) from BioLegend. Cells were alternatively fixed in 
Foxp3 fixation buffer (eBioscience), and incubated in Perm Buffer containing fluorochrome-
conjugated antibodies: GATA-3 PE (TWAJ), T-bet-PE-Cyanine7 (4B10) (eBioscience) and 
ROR-γt-PE-CF594 (Q31-378) (BD). 100,000 events were collected and analyzed on an LSR 
II flow cytometer (BD Biosciences). Compensation controls were prepared with OneComp 
eBeads (eBioscience). Data analyses were performed using FlowJo 7.6.5 software (TreeStar 
Inc.).
EpiDerm Skin Model
The EpiDerm human epidermis tissues (EPI-200) were purchased from MatTek 
Corporation. The source of the commercially available tissues was a single human donor. 
Upon receipt, EpiDerm tissue inserts were incubated (4°C) for 1–2h, and incubated 
overnight (37°C/5% CO2) in 6-well tissue culture plates in 0.9 ml prewarmed (37°C) serum-
free assay medium (MatTek Corp). Supernatants were collected and tissues were rinsed with 
Dulbecco’s PBS (DPBS) without calcium and magnesium (MatTek Corp). After removing 
the DPBS, 0.9 ml prewarmed assay media was added beneath each cell culture insert. 
Triclosan was added in 30 μl volumes atop the cell culture inserts (n=3) and the plates were 
returned to the incubator for 24 h. These studies were repeated with tissues from separate 
donors to confirm the results (data not shown).
Real-Time PCR
Ears (1 per mouse) or LN were mechanically disrupted on a TissueLyser II in Buffer RLT 
(Qiagen). Qiazol (ears) or chloroform (LN and EpiDerm) was added to the tissue 
homogenates, then vortexed and centrifuged for 10min at 12000×g (4°C). Total RNA was 
extracted from the aqueous phase using Qiagen’s RNeasy mini spin column kits with DNase 
treatment on a QIAcube work station. RNA concentrations and purity were analyzed on a 
NanoDrop spectrophotometer (Thermo Scientific). cDNA was prepared on an Eppendorf 
Mastercycler using Applied Biosystems’ High Capacity Reverse Transcription Kit. The 
cDNA was used as template for real-time PCR reactions containing TaqMan PCR Master 
Mix with gene-specific primers (Applied Biosystems) on a 7500 Real-Time PCR System. 
Relative fold changes in gene expression (2−ΔΔCT) was determined compared with acetone 
controls unless otherwise indicated and normalized for expression of housekeeping gene 
Actb (mouse) or GAPDH (human).
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Lactate dehydrogenase (LDH) was measured in 10 μl of EpiDerm culture supernatants using 
BioVision’s LDH-Cytotoxicity Colorimetric Assay kit II. Absorbance (450 nm) was 
measured using a SpectraMax plate reader (Molecular Devices) with background 
subtraction.
Statistical Analyses
Statistical analyses were generated using SAS/STAT software, version 9.3 (SAS Institute). 
Data were analyzed with either 1-way (triclosan concentration) or 2-way (triclosan by day or 
immune parameter) analysis of variance using PROC MIXED. In some cases data were 
transformed using the natural log to meet the assumptions of the analysis. Significant 
interactions were explored utilizing the “slice” option in PROC MIXED, and pairwise 
differences were assessed using Fishers Least Significant Difference Test. Significant 
differences are indicated as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
RESULTS
Kinetic Changes in Cytokine Expression in Skin Tissue With Repeated Triclosan Exposure
For these studies, triclosan was applied at 0.75% or 3% in acetone to the dorsal surface of 
both ear pinnae of BALB/c mice every 24 h for up to 12 days. These concentrations were 
previously found to enhance allergic responses in a mouse OVA asthma model (Anderson et 
al., 2012). The majority of mice dosed with 3% triclosan exhibited some mild skin irritation 
(Supplementary Fig. S1); these effects were typically observed after 4 days of repeated 
exposure, and peaked in severity after approximately 9 days. The skin of mice dosed with 
0.75% triclosan generally appeared normal, however approximately 20% of the mice 
exhibited some mild skin irritation. Sections of ear pinnae from mice dosed with 3% 
triclosan (n=5) were further examined which revealed formation of epidermal keratocellular 
crust (4/5), keratosis (3/5), hyperplasia (5/5), subcorneal/superficial pustules (3/5), and 
dermal mixed inflammatory cell infiltrates (4/5). Histopathological changes associated with 
0.75% triclosan were of minimal severity and lower incidence (1/5) than with 3%.
Next, we examined the cytokine expression kinetics in the skin tissue with repeated topical 
application of triclosan. To maintain consistency between studies, mice were also sensitized 
to OVA by intraperitoneal injection on Day 0 to help identify effects on antigen-specific 
responses. The histopathological effects of triclosan on the ear tissue were consistent 
regardless of OVA administration (Supplementary Fig. S2A). Dermal dosing was initiated 
on Day −2 thus the analyses shown for Days 2–10 reflect 4–12 days of repeat dosing, 
respectively. Changes in cytokine gene expression were first measured in the cDNA by 
realtime PCR which identified dose-dependent increases in the expression of Tslp, Il6, Il1b, 
and Tnfa with concomitant decreases in Il25 and Il33 (Supplementary Fig. S2). Soluble 
proteins were extracted from the ear tissue and found to increase by 3-fold in total protein 
concentrations by Day 10 after 3% dosing compared with controls (Fig. 1A). After 
normalizing total protein concentrations, TSLP was the only cytokine identified to increase 
significantly by Day 2 and remain increased (3%) (Fig. 1B). Although Tslp was upregulated 
3-fold in the skin with 0.75% triclosan exposure (Supplementary Fig. S2), changes in TSLP 
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protein expression were not significant. Inflammatory cytokines IL-1β and TNF-α were 
significantly increased by Day 7 (3%) which correlated with increased skin irritation. 
Conversely, IL-25, IL-33, and IL-1α expression were significantly decreased by Day 7 
(3%). IL-22 was not detected in controls, but was detected at low concentrations with 
triclosan exposure. IL-4 was also detected by Day 10 along with small decreases in IL-2 
(3%). Other cytokines below limits of detection included IFN-γ, GM-CSF, IL-5, IL-6, 
IL-10, and IL-17A. Increased TSLP, IL-1β, and TNF-α expression in concert with decreased 
IL-1α, IL-25, and IL-33 expression suggests a unique cytokine expression signature is 
induced in skin tissue with repeated triclosan exposure.
Cytokine gene expression changes were then measured in a primary human skin tissue 
model (EpiDerm) after triclosan application. A range of 2-fold dilutions of triclosan were 
applied (0%–0.75%) and tissues were examined after 24h. Concentrations of triclosan ≥ 
0.188% were toxic as measured by high lactate dehydrogenase (LDH) release (Fig. 1C) and 
poor RNA recovery (data not shown). At concentrations ≤ 0.094%, there were some 
increases in LDH release compared with acetone control, however RNA recovery was 
comparable thus the effects of triclosan were further assessed at concentrations between 0 
and 0.1%. Interestingly, 24h after application of 0.1% triclosan, TSLP, and IL1B transcripts 
were upregulated 5-fold and 2-fold respectively (Fig. 1D). IL33 transcript was down-
regulated in tissues exposed to both 0.1% and 0.05% triclosan. These results were consistent 
with the mouse ear tissue, but conversely, TNFA expression was decreased and IL1A was 
increased. The expression of IL6, IL22, and IL25 were below limits of detection.
Repeated Exposure to Triclosan Enhances Adaptive Immune Responses and Cytokine 
Expression in the Skin Draining LN
Next, the effects of triclosan on the skin draining LN were examined. There were significant 
dose-dependent increases in LN cellularity that peaked at Day 7 (Fig. 2A). Increased LN 
cellularity also occurred in non-OVA-sensitized mice dosed with triclosan (Supplementary 
Fig S2B). Further phenotypic analysis of the LN revealed a significant increase in the 
frequency of B cells across all time points (Fig. 2B). On Day 2 after OVA sensitization, 
there was a significant increase in the frequency of CD11bhigh MHC II+ DCs (3%) and dose-
dependent increases in the numbers of B cells, CD4 T cells, CD8 T cells, and DCs that 
peaked at Day 7 (Fig. 2C). There were also significant increases in cytokine production by T 
cells from LN exposed to triclosan (Fig. 3A). By Day 2, IL-2, IFN-γ (0.75% and 3%) and 
IL-17A and IL-22 (3%) were significantly increased. By Day 4, IL-17A concentrations were 
also increased with 0.75% triclosan exposure. By Day 7, concentrations of IL-17A were still 
increased relative to controls; however significant increases in IL-4 (3%) and IL-13 (0.75% 
and 3%) emerged indicating a shift toward Th2 cytokine production. Other cytokines 
including IL-6, IL-10, IL-1α, and IL-21 were below limits of detection.
Additional phenotyping of the LN CD4 T cells revealed a subset that expressed high levels 
of CD44 across all time points (3%) (Fig. 3B). These cells were also CCR7low and 
CD62Llow (data not shown) suggesting this polyclonal CD4 T cell population consisted of 
primary effectors and/or effector memory T cells that had emerged or were recruited to the 
site. Intracellular cytokine staining (ICS) revealed that CD4 T cells were the primary 
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producers of cytokines detected in the supernatants including IL-4, IL-13, TNF-α, and 
IL-17A, with some production of IL-2 and IFN-γ (Fig. 3C). CD8 T cells were the primary 
producers of IFN-γ (data not shown). ICS staining for IL-5 and IL-22 expression was not 
sufficient to identify positive subsets. Examining co-expression of CD44 revealed the 
CD44high CD4 T cells were a major source of IL-4, IL-13, IL-17, and IFN-γ, whereas IL-2 
and TNF-α were produced by CD44low and CD44high CD4 T cells (Fig. 2D). Interestingly, 
co-ICS staining revealed mutually exclusive IL-13+IL-4+ and IL-17+IL-4neg CD44high CD4 
T cell subsets in the LN on Day 7 (Fig. 2E). Expression of IFN-γ, IL-2, and TNF-α was not 
unique to either of the 2 CD4 T cell subsets suggesting different functional roles for IL-17 
and IL-4 in the responses to dermal triclosan exposure.
Dermal Exposure to Triclosan Promotes Th2 Responses in LN
Next, expression of transcription factors associated with different effector CD4 T cell 
subsets were measured including T-bet (Th1), GATA-3 (Th2), and ROR-γt (Th17). This 
revealed a CD4 T cell subset that expressed high levels of GATA-3 (Fig. 4A). The mean 
fluorescence intensity (MFI) of GATA-3 expression in LN CD4 T cells was dose-
dependently increased on Day 4 with triclosan exposure (Fig. 4B) and the GATA-3high 
subset was not found in the spleen or in other peripheral LN (Fig. 4C). The GATA-3high 
CD4 T cells also expressed OX40 which was increased both as a percentage of cells (0.75% 
and 3%) and MFI (3%) in both OVA-sensitized and nonsensitized mice (Fig. 4D and E, 
Supplementary Fig. S2C). Ox40l transcript was also detected in the LN and found to be 
increased 2-fold with 3% triclosan exposure although changes in protein expression were 
not detected (data not shown). It should also be noted that changes in Foxp3 (Treg) and 
Bcl-6 (TFH) populations were unremarkable.
We postulated that CD4 T cells with known antigen specificity could be influenced by 
triclosan and skewed towards a Th2 phenotype in vivo. OVA-specific CD4 T cells (KJ126+) 
were adoptively transferred from transgenic DO11.10 mice into BALB/c mice that were 
then sensitized to OVA and dosed dermally with triclosan. KJ126+ CD4 T cells identified in 
the spleen and LN were CD44+ and consisted of 2% of the CD4 T cells on Day 4 after 
sensitization (Fig. 5A). The numbers of KJ126+ CD4 T cells in both tissues also peaked at 
Day 4 with significantly more in the LN of mice exposed to 3% triclosan (Fig. 5B). 
Interestingly, on Day 2 there was a transient dose-dependent increase in the GATA-3 MFI in 
LN KJ126+ CD4 T cells that was not observed in the spleen (Fig. 5C). Thus CD4 T cells 
responding to OVA could be further skewed towards a Th2 phenotype when influenced by 
dermal triclosan exposure.
Dermal Exposure to Triclosan Enhances the Expression of Activation Markers on APCs in 
the LN
Significant increases in the numbers of B cells and DCs in the LN suggested that triclosan 
may also affect their expression of activation markers. Dose-dependent increases in the 
percentage of DCs that expressed CD80 and CD86 were observed after 4 days of repeated 
triclosan exposure (Fig. 6A). CD40 was also expressed by the DCs however expression was 
not different (data not shown). There was also a dose-dependent increase in the percentage 
of B cells expressing CD86 that increased dramatically by Day 4 and remained increased 
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(Fig. 6B). The MFI of GL-7 expression, a marker for germinal center B cells, was also 
significantly increased by Day 9 (3%) (Fig. 6C). These effects on APCs were not observed 
for any time-point in the spleen.
In Vivo Antibody Blockade of TSLP Impairs Allergic Responses in the Skin and LN 
Augmented by Triclosan
TSLP is established to play an important role in allergic Th2 responses. After measuring 
early and sustained TSLP expression in the skin tissue, we employed a neutralizing antibody 
to determine the role of TSLP in the effects of dermal triclosan exposure. Mice were dosed 
with 0% or 3% triclosan and injected with anti-TSLP or isotype control antibodies at 3 day 
intervals as outlined in Figure 7A. On Day 7, evaluation of ear pinnae tissue sections 
revealed that anti-TSLP treatment (200 μg) reduced the histopathological effects observed 
with 3% triclosan exposure including decreased hyperplasia and inflammatory cell infiltrate 
(Fig. 7B). Little to no TSLP protein was detected in the ear tissue of mice dosed with 3% 
triclosan and injected with anti-TSLP (400 μg) (Fig. 7C); however at the transcript level, 
Tslp was increased 2-fold compared with isotype controls which may indicate a positive 
feedback loop for TSLP expression (Supplementary Fig. S4A). The lack of TSLP protein 
detection by sandwich ELISA was likely due in part to interference by the injected anti-
TSLP antibody present in the ear tissue lysates. IL-1β protein expression was also 
significantly decreased with anti-TSLP treatment, but no significant changes were observed 
for IL-1α, IL-22, IL-25, IL-33, or TNF-α transcript and protein (Fig. 7C, Supplementary 
Fig. S4). Il4 transcript, only detected in the 3% group, was decreased by half with anti-TSLP 
treatment (Supplementary Fig. S4B).
Next, we examined the effects of blocking TSLP activity on the LN. With anti-TSLP 
treatment, there was a significant decrease in the total number of LN cells with 3% dosing 
(Fig. 8A), including significant decreases in the numbers of B cells and DCs (Fig. 8B). 
Although the number of T cells was not different, there was a significant decrease in the 
GATA-3 MFI with anti-TSLP treatment (Fig. 8C). The MFI of OX40 expression was also 
decreased with anti-TSLP treatment but was not significant (P=.08). A significant decrease 
in the frequency of CD44high CD4 T cells which, albeit small, was repeatable with anti-
TSLP treatment (Fig. 8C). Anti-TSLP treatment also induced significant increases in TNF-α 
and significant decreases in IL-5 production by LN T cells with no effects on IL-22, IL-17A, 
IL-2, or IFN-γ (Fig. 8D). Changes in cytokine gene transcript expression also revealed 
greater than 2-fold decreases in Il4 and Il13 in LN cells with anti-TSLP treatment (Fig. 8E). 
The results of blocking TSLP activity in vivo suggests TSLP plays an important role in 
augmenting Th2 allergic responses with triclosan exposure. The molecular and cellular 
changes we observed in the skin tissue and draining LN with dermal triclosan exposure are 
collectively summarized in an illustration (Fig. 9).
DISCUSSION
As the prevalence of allergic disease continues to rise in Westernized countries (Graham-
Rowe, 2011), the roles of lifestyle factors including exposures to chemicals in products that 
we use at home and the workplace are under increasing scrutiny. Triclosan is ubiquitous, 
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detected in >75% of individuals in the United States (Calafat, et al., 2008) and over 50% of 
U.S. waterways (Kolpin et al., 2002). Although not classified as a chemical sensitizer, there 
have been increasing reports associating triclosan exposure and allergic disease (Anderson, 
et al., 2012; Bertelsen, et al., 2013; Clayton, et al., 2011; Savage, et al., 2014; Savage, et al., 
2012; Spanier, et al., 2014). Here we show that topical application of triclosan induces 
expression of TSLP, IL-1β, and TNF-α in skin tissue of BALB/c mice. TSLP is expressed 
by different cell types including epithelial cells, keratinocytes and DCs (Ziegler et al., 2013) 
and is induced as an integral part of cellular and immune responses to skin barrier damage 
(Angelova-Fischer et al., 2010; Oyoshi et al., 2010). In primary human EpiDerm skin 
tissues, we also found increases in TSLP and IL1B transcripts with decreased expression of 
IL33 suggesting dermal triclosan exposure can act directly on keratinocytes to alter cytokine 
expression. Similar results were also obtained after treating EpiDerm skin tissues from a 
second donor (data not shown). In contrast with the intact mouse skin tissues, we identified a 
decrease in TNFA expression and an increase in IIL1A expression in the cultured tissues 
with triclosan exposure. The lack of inflammatory cell infiltrate in the EpiDerm tissue 
compared with the intact mouse skin tissue may account for these differences as infiltrating 
cells can produce and/or regulate cytokine expression in the skin. Curiously, there was a 
very small range of triclosan concentrations that produced measurable biological effects in 
the EpiDerm tissue system as little effects on gene expression were observed at 0.05% with 
marked toxicity at 0.2% by 24h. This observation, along with the potential for donor 
variability highlights the limitations of using this model system for studies of dermal 
triclosan exposure.
In vivo, TSLP was found to play an important role in augmenting allergic responses with 
dermal triclosan exposure. Through the use of in vivo antibody blockade, we found that 
TSLP promoted inflammatory responses in the skin tissue including IL-1β expression. In the 
LN, TSLP promoted the development and/or recruitment of activated DCs, B cells, and Th2 
cells. OVA-specific KJ126+ CD4 T cells in the local LN were further skewed towards a Th2 
phenotype with triclosan exposure as evidenced by dose-dependent increases in GATA-3 
expression which may offer a potential mechanism for how triclosan augments allergic 
responses. The effects of triclosan on GATA-3 expression in KJ126+ cells in the LN was 
observed transiently on Day 2, whereas increases in GATA-3 expression in the endogenous 
polyclonal CD4 T cells was observed later on Day 4. Interestingly, the Th2 cells did not 
require sustained high levels of GATA-3 expression to later produce Th2 cytokines (IL-4 
and IL-13) at Days 7 and 10.
The Th2 cell subset also expressed OX40 which is consistent with reports that TSLP 
activates DCs to prime Th2 cells (Soumelis et al., 2002) in part through OX40-OX40L 
interactions (Ito et al., 2005). OX40 is an important costimulatory molecule for promoting 
effector and memory T cell responses in allergic disease (Jember et al., 2001; Salek-
Ardakani et al., 2003), including TSLP-mediated Th2 responses (Seshasayee et al., 2007). 
IL-4, IL-13, and TNF-α have also been shown to promote TSLP expression in mouse 
keratinocytes which may reinforce an allergic response feedback loop (Bogiatzi et al., 2007; 
Dewas et al., 2015). An IL-17A+ CD4 T cell subset was also identified in the LN that 
emerged early in the response. This subset was distinct from the IL-4+IL-13+ Th2 subset as 
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determined by co-ICS staining. IL-17A production was not affected by antibody blockade of 
TSLP suggesting that the generation or recruitment of the IL-17A+ CD4 T cell subset is 
TSLP-independent and that other mechanisms could play a role in the early responses to 
dermal triclosan exposure.
TSLP also plays a pivotal role in promoting allergic responses to OVA in the lungs (Al-
Shami et al., 2005; Zhou et al., 2005). For this reason, we were unable to use a systemic 
TSLP blockade approach to determine the role of TSLP in augmenting responses to OVA in 
the lung with dermal triclosan exposure as OVA-specific immune responses would be 
severely impaired in control mice. Treatment with anti-TSLP was recently shown to reduce 
allergen-induced bronchoconstriction and indexes of airway inflammation in asthmatic 
patients (Gauvreau et al., 2014) and responses in the lung to house dust mite antigen in mice 
(Chen et al., 2013). Intradermal administration of TSLP promoted the progression from 
atopic dermatitis to asthma (Han et al., 2012) and over-expression of TSLP in keratinocytes 
(Yoo et al., 2005) promotes allergic airway inflammation in mice (Demehri et al., 2009; 
Zhang et al., 2009). Thus increased TSLP expression in skin tissue induced by repeated 
dermal triclosan exposure may also promote augmented allergic responses in the lung.
Mice dosed with 3% triclosan exhibited skin irritation that peaked in severity after 9 days of 
exposure. Similarly, individuals that used 2% triclosan hand washing cream (Ayliffe et al., 
1988) and 25% of subjects who used a 2% triclosan soap reported irritation of the skin 
(Bendig, 1990). Studies of repeated dermal triclosan exposure with B6C3F1 (B6) mice 
describe similar skin irritation that occurred as early as Day 4 (Fang et al., 2014) and 
resolved by Day 28 (Anderson et al., 2015), likely due in part to the protection provided by 
the repaired skin. With repeated application of 0.75% triclosan, we observed little skin 
irritation, however significant effects still occurred in the skin and LN including increased 
expression of Tslp and Tnfa in the skin tissue, increases in cellularity of the skin draining 
LN, increased IL-4, IL-17A, IL-22, IFN-γ, and GATA-3 expression by CD4 T cells and 
increases in CD80 and CD86 expression on LN DCs and B cells. Thus topical application of 
triclosan produces measurable immunomodulatory effects even in the absence of overt skin 
irritation which is important to consider as triclosan is incorporated into products within a 
range of 0.1–1%.
The mechanism of action of triclosan, particularly at lower concentrations, is targeted 
inhibition of the Fab I gene of the bacterial type II fatty acid synthesis pathway which 
reduces bacterial viability (Heath et al., 1999; Levy et al., 1999; McMurry et al., 1998). The 
effects of triclosan on host microbial flora (microbiome) has not yet been well described; 
however, data are emerging that suggest disruption of the microbiome can play a role in 
allergic disease (Hoskin-Parr et al., 2013; Kong et al., 2012). Interestingly, mice housed in a 
germ-free (GF) environment were found to express significantly higher levels of TSLP in 
their skin compared with those housed in specific pathogen-free conditions (Yockey et al., 
2013). Asthma and allergies have a complex etiology determined by a combination of host 
genetic and environmental factors. TSLP could be a relevant biomarker in skin tissue for 
identifying chemicals with potential immunomodulatory health effects like triclosan. With 
increasing evidence of health effects resulting from exposures to antimicrobial chemicals, 
we must continue to carefully consider how best to balance infection control practices with 
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the potential health risks associated with overuse of antimicrobial chemicals to protect 
healthcare workers and the general population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The findings and conclusions in this report are those of the author and do not necessarily represent the views of the 
National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.
FUNDING:
This work was supported by National Institute for Occupational Safety and Health intramural funding (CAN 
number 927ZLCU).
References
Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of 
inflammation in an asthma model. J Exp Med. 2005; 202:829–839. [PubMed: 16172260] 
Anderson SE, Franko J, Kashon ML, Anderson KL, Hubbs AF, Lukomska E, Meade BJ. Exposure to 
Triclosan Augments the Allergic Response to Ovalbumin in a Mouse Model of Asthma. Toxicol Sci 
Off J Soc Toxicol. 2012; 132:96–106.
Anderson SE, Meade BJ, Long CM, Lukomska E, Marshall NB. Investigations of immunotoxicity and 
allergic potential induced by topical application of triclosan in mice. J Immunotoxicol. 2015:1–
8.10.3109/1547691x.2015.1029146
Angelova-Fischer I, Fernandez IM, Donnadieu MH, Bulfone-Paus S, Zillikens D, Fischer TW, 
Soumelis V. Injury to the stratum corneum induces in vivo expression of human thymic stromal 
lymphopoietin in the epidermis. J Invest Dermatol. 2010; 130:2505–2507. [PubMed: 20555350] 
Ayliffe GA, Babb JR, Davies JG, Lilly HA. Hand disinfection: a comparison of various agents in 
laboratory and ward studies. J Hospital Infect. 1988; 11:226–243.
Bendig JW. Surgical hand disinfection: comparison of 4% chlorhexidine detergent solution and 2% 
triclosan detergent solution. J Hospital Infect. 1990; 15:143–148.
Bertelsen RJ, Longnecker MP, Lovik M, Calafat AM, Carlsen KH, London SJ, Lodrup Carlsen KC. 
Triclosan exposure and allergic sensitization in Norwegian children. Allergy. 2013; 68:84–91. 
[PubMed: 23146048] 
Bogiatzi, SI.; Fernandez, I.; Bichet, JC.; Marloie-Provost, MA.; Volpe, E.; Sastre, X.; Soumelis, V. J 
Immunol. Vol. 178. Baltimore, Md: 2007. 1950. Cutting Edge: proinflammatory and Th2 cytokines 
synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes; p. 
3373-3377.
Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Urinary concentrations of triclosan in the U.S. 
population: 2003–2004. Environ Health Perspect. 2008; 116:303–307. [PubMed: 18335095] 
Chen ZG, Zhang TT, Li HT, Chen FH, Zou XL, Ji JZ, Chen H. Neutralization of TSLP inhibits airway 
remodeling in a murine model of allergic asthma induced by chronic exposure to house dust mite. 
PloS One. 2013; 8:e51268. [PubMed: 23300949] 
Clayton EM, Todd M, Dowd JB, Aiello AE. The impact of bisphenol A and triclosan on immune 
parameters in the U.S. population, NHANES 2003–2006. Environ Health Perspect. 2011; 
119:390–396. [PubMed: 21062687] 
Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from 
epidermal-barrier defects to asthma. PLoS Biol. 2009; 7:e1000067. [PubMed: 19557146] 
Dewas C, Chen X, Honda T, Junttila I, Linton J, Udey MC, Porcella SF, Sturdevant DE, Feigenbaum 
L, Koo L, et al. TSLP Expression: Analysis with a ZsGreen TSLP Reporter Mouse. J Immunol. 
2015; 194:1372–1380. [PubMed: 25539812] 
Marshall et al. Page 11













Fang JL, Vanlandingham M, da Costa GG, Beland FA. Absorption and metabolism of triclosan after 
application to the skin of B6C3F1 mice. Environ Toxicol. 201410.1002/tox.22074
Gauvreau GM, O’Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, 
Boedigheimer M, Davis BE, Dias C, et al. Effects of an anti-TSLP antibody on allergen-induced 
asthmatic responses. N Engl J Med. 2014; 370:2102–2110. [PubMed: 24846652] 
Graham-Rowe D. Lifestyle: When allergies go west. Nature. 2011; 479:S2–S4. [PubMed: 22158296] 
Han H, Xu W, Headley MB, Jessup HK, Lee KS, Omori M, Comeau MR, Marshak-Rothstein A, 
Ziegler SF. Thymic stromal lymphopoietin (TSLP)-mediated dermal inflammation aggravates 
experimental asthma. Mucosal Immunol. 2012; 5:342–351. [PubMed: 22354320] 
Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO. Mechanism of triclosan inhibition of 
bacterial fatty acid synthesis. J Biol Chem. 1999; 274:11110–11114. [PubMed: 10196195] 
Hoskin-Parr L, Teyhan A, Blocker A, Henderson AJ. Antibiotic exposure in the first two years of life 
and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. 
Pediatric Allergy Immunol Off Publ Eur Soc Pediatric Allergy Immunol. 2013; 24:762–771.
Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, Qin FX, Yao Z, Cao W, Liu YJ. 
TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through 
OX40 ligand. J Exp Med. 2005; 202:1213–1223. [PubMed: 16275760] 
Jember AG, Zuberi R, Liu FT, Croft M. Development of allergic inflammation in a murine model of 
asthma is dependent on the costimulatory receptor OX40. J Exp Med. 2001; 193:387–392. 
[PubMed: 11157058] 
Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT. 
Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–
2000: a national reconnaissance. Environ Sci Technol. 2002; 36:1202–1211. [PubMed: 11944670] 
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, 
Murray PR, et al. Temporal shifts in the skin microbiome associated with disease flares and 
treatment in children with atopic dermatitis. Genome Res. 2012; 22:850–859. [PubMed: 
22310478] 
Lachapelle JM, Tennstedt D. Low allergenicity of triclosan. Predictive testing in guinea pigs and in 
humans. Dermatologica. 1979; 158:379–383. [PubMed: 374145] 
Levy CW, Roujeinikova A, Sedelnikova S, Baker PJ, Stuitje AR, Slabas AR, Rice DW, Rafferty JB. 
Molecular basis of triclosan activity. Nature. 1999; 398:383–384. [PubMed: 10201369] 
MacIsaac JK, Gerona RR, Blanc PD, Apatira L, Friesen MW, Coppolino M, Janssen S. Health care 
worker exposures to the antibacterial agent triclosan. J Occupat Environ Med Am College Occupat 
Environ Med. 2014; 56:834–839.
McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature. 1998; 394:531–532. 
[PubMed: 9707111] 
Oyoshi MK, Larson RP, Ziegler SF, Geha RS. Mechanical injury polarizes skin dendritic cells to elicit 
a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin 
Immunol. 2010; 126:976–984. 984 e1–5. [PubMed: 21050944] 
Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, Yagita H, Croft M. OX40 (CD134) 
controls memory T helper 2 cells that drive lung inflammation. J Exp Med. 2003; 198:315–324. 
[PubMed: 12860930] 
Savage JH, Matsui EC, Wood RA, Keet CA. Urinary levels of triclosan and parabens are associated 
with aeroallergen and food sensitization. J Allergy Clin Immunol. 2012; 130:453–460 e7. 
[PubMed: 22704536] 
Savage JH, Johns CB, Hauser R, Litonjua AA. Urinary triclosan levels and recent asthma 
exacerbations. Anna Allergy Asthma Immunol Off Publ Am College Allergy Asthma Immunol. 
2014; 112:179–181 e2.
Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, et al. In vivo 
blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J 
Clin Invest. 2007; 117:3868–3878. [PubMed: 18060034] 
Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, 
Lauerma A, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by 
producing TSLP. Nat Immunol. 2002; 3:673–680. [PubMed: 12055625] 
Marshall et al. Page 12













Spanier AJ, Fausnight T, Camacho TF, Braun JM. The associations of triclosan and paraben exposure 
with allergen sensitization and wheeze in children. Allergy Asthma Proc Off J Regional State 
Allergy Soc. 2014; 35:475–481.
Yockey LJ, Demehri S, Turkoz M, Turkoz A, Ahern PP, Jassim O, Manivasagam S, Kearney JF, 
Gordon JI, Kopan R. The absence of a microbiota enhances TSLP expression in mice with 
defective skin barrier but does not affect the severity of their allergic inflammation. J Invest 
Dermat. 2013; 133:2714–2721.
Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, Comeau MR, Campbell DJ, Ziegler SF. 
Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin 
transgene specifically in the skin. J Exp Med. 2005; 202:541–549. [PubMed: 16103410] 
Zhang Z, Hener P, Frossard N, Kato S, Metzger D, Li M, Chambon P. Thymic stromal lymphopoietin 
overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci 
USA. 2009; 106:1536–1541. [PubMed: 19188585] 
Zhou B, Comeau MR, De Smedt T, Liggitt HD, Dahl ME, Lewis DB, Gyarmati D, Aye T, Campbell 
DJ, Ziegler SF. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in 
mice. Nat Immunol. 2005; 6:1047–1453. [PubMed: 16142237] 
Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H. The biology of thymic stromal 
lymphopoietin (TSLP). Adv Pharmacol. 2013; 66:129–155. [PubMed: 23433457] 
Marshall et al. Page 13














Kinetic changes in cytokine expression in skin tissue with repeated dermal triclosan 
exposure. Concentrations of soluble protein (A) and cytokines (B) extracted from the ear 
pinnae of OVA-sensitized mice after daily dosing with 0% (circle), 0.75% (square) or 3% 
(triangle) triclosan (n=6 mice). Data are representative of two independent time-course 
studies. LDH released into supernatants of EpiDerm tissues prior to (pretreatment) or after 
exposure to triclosan dissolved in acetone (n=3 wells) (C). Fold-change in gene expression 
relative to acetone control (0%) in EpiDerm tissues 24h after application of 0.05% or 0.1% 
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triclosan (n=3 wells) (D). Data are representative of two independent studies utilizing 
different donor tissues. Bars represent the mean ± SEM, with statistical significance 
indicated as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
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Repeated dermal exposure to triclosan promotes adaptive immune responses in the skin 
draining LN. Total number of LN cells (A), frequencies (B) and numbers (C) of specific 
leukocyte subsets in the LN of OVA-sensitized mice after daily dosing with 0% (circle), 
0.75% (square) or 3% (triangle) triclosan (n=4 mice). Data are representative of 3 
independent studies. Bars represent the mean ± SEM, with statistical significance indicated 
as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
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Repeated dermal exposure to triclosan augments cytokine production by activated LN CD4 
T cells. Cytokine concentrations in LN cell supernatants (A) and percentage of LN CD4T 
cells expressing high levels of CD44 (B) from mice dosed daily with 0% (square), 0.75% 
(triangle) or 3.0% (inverted triangle) triclosan (n=4 mice) (A). Representative two-parameter 
histogram plots of LN CD4 T cell ICS staining from mice dosed daily with 3% triclosan and 
harvested Day 7 (C, D, E), versus CD44 expression (D) and in CD44+ CD4 T cells (E). Data 
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are representative of 3 independent studies. Bars represent the mean ± SEM, with statistical 
significance indicated as P ≤ .05 (*), P≤ .01 (**), P≤ .001 (***), and P≤ .0001 (****).
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Dermal exposure to triclosan promotes Th2 responses in the LN. Representative two-
parameter histogram plots of LN CD4 T cell ICS staining from OVA-sensitized mice dosed 
with 3% triclosan and harvested Day 7 (A) or Day 4 (n=3 mice) (B). GATA-3 expression in 
CD4 T cells from superficial cervical LN (LN), mesenteric LN (mLN) or spleen (Spl) on 
Day 7 (C). OX40 MFI on LN CD4 T cells Day 7 and percentage of LN CD4 T cells 
expressing OX40 after daily dosing with 0% (square), 0.75% (triangle) or 3% (inverted 
triangle) triclosan (n=4–5 mice) (E). Data are representative of 3 independent studies. Bars 
represent the mean ± SEM, with statistical significance indicated as P ≤ .05 (*), P ≤ .01 
(**), P ≤ .001 (***), and P ≤ .0001 (****).
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Dermal exposure to triclosan promotes OVA-specific Th2 responses in the LN. CD4 T cells 
from DO11.10 mice (KJ126+) adoptively transferred into BALB/c mice as a percentage of 
total CD4 T cells (A), and number (B) in the spleen and LN with 0% (square), 0.75% 
(triangle) or 3% (inverted triangle) daily triclosan dosing (n=4 mice). GATA-3 MFI of 
KJ126+ LN or spleen CD4 T cells and representative overlay histogram of GATA-3 
expression in KJ126+ LN CD4 T cell on Day 2 (C). Data are representative of two 
independent studies. Bars represent the mean ± SEM, with statistical significance indicated 
as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
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Dermal exposure to triclosan increases the expression of activation markers on antigen 
presenting cells in the LN. Frequencies of CD80+ and CD86+ LN DCs from OVA-sensitized 
mice after 4 days of triclosan dosing (A) and frequency of CD86+ LN B cells in mice dosed 
daily with 0% (square), 0.75% (triangle) or 3% (inverted triangle) triclosan (B) (n=3–4 
mice). GL-7 staining MFI and overlay histogram for LN B cells on Day 9 (C) (n=5 mice). 
Each data point reflects analyses of the LN from an individual mouse (A, B, C). Data are 
representative of 3 independent studies. Bars represent the mean ± SEM, with statistical 
significance indicated as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
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In vivo antibody blockade of TSLP impairs allergic responses in the skin augmented by 
triclosan. Timeline of treatments to OVA-sensitized mice co-treated with anti-TSLP or 
isotype control antibodies and dosed daily with triclosan (A). Representative 
photomicrographs of H&E-stained ear pinnae tissue sections (B) and concentrations of 
cytokine in ear protein lysates of mice dosed daily with 0% or 3% triclosan and co-treated 
with anti-TSLP (square) or isotype control (circle) antibodies (n=4–6 mice) (C). Each data 
point reflects analyses of an ear from an individual mouse (C). Data are representative of 
two independent studies. Bars represent the mean ± SEM, with statistical significance 
indicated as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
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In vivo antibody blockade of TSLP impairs allergic responses in the LN augmented by 
triclosan. The total number of LN cells (A), numbers of leukocyte subsets (B) and proteins 
expressed by LN CD4 T cells (C) on Day 7 from mice dosed with 0% or 3% triclosan and 
co-treated with anti-TSLP (square) or isotype control (circle) (n=4–6 mice). Cytokine 
concentrations in supernatants collected from the LN cells stimulated for 24h (D). Fold 
changes in cytokine gene expression in LN cDNA relative to 0% control (E). Data are 
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representative of two independent studies. Bars represent the mean ± SEM, with statistical 
significance indicated as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), and P ≤ .0001 (****).
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Summary of the effects of dermal triclosan exposure on the skin and LN. A schematic 
representation of the effects of repeated dermal triclosan exposure on gene expression and 
cellularity in the skin and LN.
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